Chesterford Research Park
Little Chesterford CB10 1XL
United Kingdom
44 1223 426 060
https://arecor.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 51
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Sarah Jennifer Howell Ph.D. | CEO & Director | 421k | 51.46k | 1975 |
Ms. Susan Day Lowther FCMA | CFO, Company Secretary & Director | 306k | 154.38k | 1960 |
Dr. Jan Jezek Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Mr. David Gerring | Senior Vice President of Development | N/A | N/A | N/A |
Dr. Manjit Rahelu Ph.D. | Chief Business Officer | N/A | N/A | N/A |
Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo, a ready-to-use glucagon auto-injector pen that is used to treat hypoglycaemia in patients with diabetes; and specialty hospital care products. In addition, the company is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Arecor Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.